Assertio publishes Rolvedon same-day dosing study in The Oncologist Jan 9, 2026 02:00PM
Assertio Therapeutics (ASRT) PT Raised to $35 at H.C. Wainwright Jan 5, 2026 06:41AM
Assertio Therapeutics (ASRT) Tops Q3 EPS by 27c, provides guidance Nov 10, 2025 04:18PM
Assertio names Mark Reisenauer as new CEO Oct 28, 2025 09:15AM
Assertio Therapeutics (ASRT) PT Lowered to $3 at H.C. Wainwright Aug 12, 2025 06:42AM


Aug 11, 2025 04:07PM Assertio Therapeutics (ASRT) Tops Q2 EPS by 10c
May 13, 2025 07:42AM Assertio Therapeutics (ASRT) Misses Q1 EPS by 9c
Mar 19, 2025 06:39AM Assertio Therapeutics (ASRT) PT Lowered to $3.50 at H.C. Wainwright
Mar 12, 2025 04:11PM Assertio Therapeutics (ASRT) Tops Q4 EPS by 1c ; Offers Guidance
Dec 17, 2024 08:32AM Assertio Holdings (ASRT) Appoints Mark Reisenauer to its Board
Dec 16, 2024 06:54AM H.C. Wainwright Reiterates Buy Rating on Assertio Therapeutics (ASRT)
Dec 13, 2024 08:00AM Assertio Holdings (ASRT) Announces Results of Rolvedon injection Same-Day Dosing Clinical Study
Nov 25, 2024 06:48AM H.C. Wainwright Reiterates Buy Rating on Assertio Therapeutics (ASRT)
Nov 11, 2024 04:02PM Assertio Therapeutics (ASRT) Tops Q3 EPS by 7c
Nov 11, 2024 07:31AM Assertio Holdings (ASRT) Issues Response to Letter from Short-seller
Nov 8, 2024 09:00AM Buxton Helmsley Issues Letter to Assertio (ASRT) Stockholders Disclosing Inversion to Short Position Following Board Refusal to Address Product-Related Fraud
Aug 7, 2024 04:16PM Assertio Therapeutics (ASRT) Tops Q2 EPS by 4c ; Offers Guidance